Our Mission
Our mission is to empower biotechnology companies to successfully commercialize their innovations, focusing on achieving both Canadian and global market success. We approach this thoughtfully and strategically, leveraging deep industry experience across Canada and beyond. Every action we take is guided by our commitment to improving patient care while meeting and exceeding the needs of stakeholders.
What we do
Market Strategy Development
Evaluating the Canadian market landscape, identifying stakeholders, and crafting tailored entry strategies.
Commercialization & Operational Execution
Supporting market entry, product launch, and commercial strategies.
Funding & Partnership Development
Connecting biotech companies to Canadian funding sources and strategic partnerships.
Regulatory Affairs Consulting
Ensuring smooth regulatory and market access through Health Canada.
Deal Valuation & Licensing Strategy
Supporting financial assessments, licensing, mergers, and acquisitions.
Government/Private Insurer Pricing & Market Access Consulting
Navigating Canada’s pricing and reimbursement system.
Operational Strategy & Business/Resource Planning
Managing financial sustainability, risk mitigation, and operational execution.
Advocacy development and Stakeholder Relations
We build trust and partnerships through ongoing communication, transparency, and responsiveness.
Our Leadership
When you engage CLSG, you work directly with our Principals, Chris Aiello and Jason Lee. Both are actively involved in strategy development and execution, bringing in subject matter experts when necessary through their extensive network across Canada and globally.
Chris Aiello
Chris is a seasoned biopharmaceutical country leader with over 20 years of experience in starting and growing innovative businesses and launching therapies across Rare Disease and Speciality Pharmaceuticals in Canada and Globally. Throughout his career, he has played a pivotal role in building and leading groundbreaking organizations. This includes the start up and launch of Amylyx Pharmaceuticals in Canada, which marked the organizations first global launch market and led to the first global regulatory approval for Albrioza in ALS, ahead of the U.S. market, a milestone widely considered a first in the Canadian biopharmaceutical industry.
In addition to his work with Amylyx, Chris has led and expanded other key businesses and therapies in Canada. His career also includes founding and leading Bioverativ in Canada and leading the Sanofi Genzyme’s Rare Disease business in Canada, as well as serving as CFO and Operations Leader for Biogen Canada. In each of these roles, Chris has led comprehensive planning, execution, market access/pricing, stakeholder relations, advocacy and strategic operational set up and growth initiatives.
Chris has deep expertise in rare diseases, having been involved with a variety of therapies including Tecfidera, the first oral first-line MS therapy, and extended half-life treatments for Hemophilia A and B, such as Alprolix and Eloctate. He has also played a central role in Enzyme replacement therapies for conditions like Gaucher disease, Fabry disease, and Pompe disease, as well as leading the launch of Cablivi for aTTP a rare blood disorder and Albrioza for ALS in Canada.
Beyond his national achievements, Chris has contributed to global initiatives and worked with commercial leadership teams around the world. He also held a seat on the Board of Directors for BIOTECanada, the national voice of Canada’s biotechnology sector.
Throughout his career, Chris has demonstrated a passion for driving innovation in healthcare, improving patient access to life-changing treatments, and leading teams to success in highly competitive markets.
Jason Lee
Jason Lee is a highly accomplished professional with extensive experience in market access, pricing, reimbursement, finance, and patient support services within the biotechnology and pharmaceutical industries. His expertise spans public and private payer engagement, multiple successful government negotiations, advocacy, and stakeholder relations. Throughout his career, Jason has been instrumental in the successful commercialization, launch and reimbursement of new rare disease therapies in Canada, with a strong focus on patient access and support services. His deep understanding of the P&L, scientific data, business and health technology assessment impacts, and business planning has enabled companies to navigate the complex Health Canada regulatory and reimbursement environments to achieve successful market entry and commercialization.
Jason has played a key role in securing market access and reimbursement for transformative therapies targeting rare diseases in Canada. This includes groundbreaking therapies like Tecfidera, the first oral first-line MS therapy, and extended half-life Hemophilia A and B treatments, Alprolix and Eloctate. He also contributed to the launch of Spinraza, the first disease-modifying therapy for SMA, and Vitrakvi, the first tumor-agnostic, biomarker-driven oncology therapy. His leadership in market access and patient support has been critical to the unprecedented first global launch of Albrioza, setting a new standard for commercialization in Canada.
Jason has worked with leading organizations such as Amylyx, Bayer, Biogen, and Lilly, where he has consistently driven successful commercialization, Government relations strategies and patient access initiatives, helping to improve the lives of patients across Canada and beyond.
Organizations we've collectively supported
